

Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany

Barbara Eker, Johannes Ortmann, Giovanni B. Migliori, Giovanni Sotgiu, Ralf Muetterlein, Rosella Centis, Harald Hoffmann, Detlef Kirsten, Tom Schaberg, Sabine Ruesch-Gerdes, and Christoph Lange, for the German TBNET Group¹

We evaluated risk factors and treatment outcomes associated with multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) in Germany in 2004–2006. In 177 (4%) of 4,557 culture-positive TB cases, *Mycobacterium tuberculosis* isolates were identified as MDR TB; an additional 7 (0.15%) met criteria for XDR TB. Of these 184 patients, 148 (80%) were born in countries of the former Soviet Union. In patients with XDR TB, hospitalization was longer (mean \pm SD 202 \pm 130 vs. 123 \pm 81 days; $p = 0.015$) and resistance to all first-line drugs was more frequent (36% vs. 86%; $p = 0.013$) than in patients with MDR TB. Seventy-four (40%) of these 184 patients received treatment with linezolid. Treatment success rates ranged from 59% for the entire cohort (59% for MDR TB and 57% for XDR TB) to 87% for those with a definitive outcome ($n = 125$; 89% for MDR TB and 80% for XDR TB). Extensive drug susceptibility testing and availability of second- and third-line drugs under inpatient management conditions permit relatively high treatment success rates in MDR and XDR TB.

Tuberculosis is among the leading causes of death worldwide. The World Health Organization (WHO) estimates that 32% of the world population is infected with *Mycobacterium tuberculosis*, the causative agent of TB (1). There were an estimated 9.2 million new TB cases and 1.7 million deaths from TB in 2006 (2).

Drug resistance to isoniazid and rifampin, the 2 most potent first-line drugs for the treatment of TB (the defini-

Author affiliations: Research Center Borstel, Borstel, Germany (B. Eker, S. Ruesch-Gerdes, C. Lange); Karl-Hansen-Clinic, Bad Lippspringe, Germany (J. Ortmann); World Health Organization Collaborating Center for TB and Lung Diseases, Tradate, Italy (G.B. Migliori, R. Centis); Sassari University, Sassari, Italy (G. Sotgiu); Regional Hospital, Pasberg, Germany (R. Muetterlein); Asklepios-Hospital, Gauting, Germany (H. Hoffmann); Hospital Großhansdorf, Großhansdorf, Germany (D. Kirsten); and Deaconess Hospital, Rotenburg, Germany (T. Schaberg)

DOI: 10.3201/eid1411.080729

tion for MDR), is increasing globally (3,4). Surveillance data indicate MDR TB is an emerging global problem, especially in countries of the former Soviet Union (FSU), Israel, and areas of the People's Republic of China (5–7). Since active TB will develop in only a proportion of persons infected with *M. tuberculosis* directly after primary infection, the prevalence of MDR TB may still be underestimated. Furthermore, strains of *M. tuberculosis* that are resistant to second-line drugs are also emerging. In vitro drug resistance of *M. tuberculosis* to any fluoroquinolone and to at least one of the injectable drugs (capreomycin, kanamycin, or amikacin), in addition to isoniazid and rifampin resistance, is defined as XDR TB (8,9). Strains of XDR TB have now been isolated from patients in >45 nations worldwide, and they are associated with worse treatment outcomes than strains of MDR TB (8,10,11). Strains of XDR TB are increasingly seen in HIV-seropositive persons with TB in southern Africa, where these strains are passed by person-to-person contact. XDR TB has become a serious problem for the health administrations in this region (12). In contrast, infections with XDR TB strains are rarely seen in Western Europe, mainly among the population of pre-treated migrants from countries of the FSU (13).

¹Additional German Tuberculosis Network European Trials group (TBNET) contributors: R. Eberhardt, Thorax-Clinic-Heidelberg, Heidelberg; A. Esselmann, Pulmonary Clinic, Hemer; H. Flick, Charité, Berlin; M. Hamm, Hospital Dieckholzen, Dieckholzen; P. Hammerl, Hospital Immenhausen, Immenhausen; H. Hang, Hospital Schillerhöhe, Schillerhöhe; P. Hannemann, Deaconess Hospital, Neustadt; D. Hillemann, Research Center Borstel, Borstel; B. Kretz, Asklepios Hospital, Gauting; C. Laumanns, Bethania Hospital, Solingen; G. Liebetau, Lostau Hospital, Lostau; S. Ott, Helios Clinic Emil von Behring, Berlin; A. Paulick, Pulmonary Clinic-Coswig, Coswig; M.W. Pletz, Hannover Medical School, Hannover; M. Rau, Pulmonary Clinic, Wangen; G. Rohde, Bergmannsheil Hospital, Bochum; A. de Roux, Evangelische Lungenklinik, Berlin; C. Schaudt, Hospital St. Blasien, St. Blasien; K-D.Schneider, Pulmonary Clinic, Hannover-East, Hannover; S. Stenger, University Hospital, Ulm; D. Wagner, University Hospital, Freiburg; and T. Wolf, University Hospital, Frankfurt.

Although the incidence of TB is steadily declining in Germany, numbers of cases with MDR TB strains are increasing. In 2006, of 3,501 TB cases in Germany for which resistance data were available, 78 (2.2%) were MDR TB (14); these cases mainly occurred among immigrants from countries with high prevalence of MDR TB (14,15).

TB surveillance data for Germany are reported annually by a national disease surveillance center, the Robert Koch Institute (14). However, data on MDR TB are only reported for in vitro first-line drug resistance against isoniazid, rifampin, ethambutol, pyrazinamide, and the injectable agent streptomycin. To ascertain risk factors associated with MDR and XDR TB and to evaluate treatment outcome in relation to level of drug resistance and level of care, we performed a retrospective survey among the network of hospitals participating in the Tuberculosis Network European Trials group (TBNET); these hospitals specialize in treating TB in Germany.

Materials and Methods

Clinical outcomes (available from the original clinical records) were evaluated by attending physicians at hospitals specialized in the care of patients with TB in Germany; they completed a standard questionnaire for all patients with culture-confirmed isoniazid and rifampin drug-resistant *M. tuberculosis* hospitalized from January 1, 2004, through December 31, 2006. The survey included information on the patients' age, gender, country of origin, HIV-seropositivity status, history of previous treatment, *M. tuberculosis* drug-resistance profile, treatment duration, and treatment outcome. Drug-susceptibility testing (DST) for first-line anti-TB drugs was performed by quality-assured laboratories. Isolates with resistances to anti-TB drugs were (re-)tested at one of the WHO's Supranational Reference Laboratories in Borstel or Gauting (16). DST for second-line drugs (ethionamide, amikacin, capreomycin, p-aminosalicylic acid, cycloserine, kanamycin) or third-line drugs (linezolid) were exclusively performed in 1 of the 2 reference centers. The BACTEC MGIT 960 (Becton Dickinson Diagnostic Systems, Sparks, MD, USA) was used for DST of first-line drugs and BACTEC MGIT 960 or the proportion method on Lowenstein-Jensen medium, or both, was used for DST of second- and third-line drugs. XDR TB was defined as resistance to isoniazid and rifampin (MDR TB definition), a fluoroquinolone, and at least one of the injectable anti-TB drugs capreomycin, kanamycin, or amikacin (17). MDR TB cases with isolates resistant to all first-line drugs were defined as those resistant to isoniazid, rifampin, ethambutol, streptomycin and, when tested, pyrazinamide.

According to Laserson criteria, a patient was defined as "cured" when he or she had completed treatment according to the country protocol and had been consistently culture-

negative (with at least 5 results) for the final 12 months of treatment; "treatment completed" when he or she had completed treatment according to the country protocol but did not meet the definition for cure or treatment failure or bacteriologic results were missing (i.e., <5 cultures were performed in the final 12 months of therapy) (18). Outcomes were compared by using the χ^2 test or Fisher exact test (categorical variables) in cases achieving a final outcome (different from default, transferred out, or still on treatment), and by using the Kaplan-Meier curve where appropriate. Logistic regression analysis was performed. The following variables were included in the statistical analysis: country, gender, HIV seropositivity, immigrant status, previous TB treatment for >30 days, DST results (ethambutol, pyrazinamide, streptomycin, any fluoroquinolone, any injectable second-line drug), and resistance to all second-line drugs. A patient was considered HIV positive, when results of the HIV-antibody ELISA (once) and at least 1 confirmatory test (Western blot or nucleic acid amplification technique) were positive.

Results

Among 4,557 culture-confirmed TB cases at 27 participating hospitals (representing 37% of all culture-confirmed cases in Germany in the 3-year period 2004–2006), 184 (4%) *M. tuberculosis* isolates were in vitro resistant at least to isoniazid and rifampin. They MDR TB isolates represented 65% of all MDR and XDR TB cases diagnosed in Germany in the study period (14,19,20). Of these cases, 177 were MDR TB, and 7 were XDR TB.

Of the 184 study patients, 174 (95%) had *M. tuberculosis* isolates resistant to streptomycin, 119 (65%) to ethambutol, 103 (56%) to rifabutin, 79 (43%) to pyrazinamide, 23 (13%) to amikacin, 20 (11%) to a fluoroquinolone, 19 (10%) to capreomycin, 36 (19%) to ethionamide, 15 (8%) to para-aminosalicylic acid, 9 (5%) to cycloserine, 3 (2%) to kanamycin, and 1 (<1%) to linezolid. Demographic and clinical characteristics are described in Table 1 and the online Appendix Table (available from www.cdc.gov/EID/content/14/11/1700-appT.htm).

Forty-five (24%) patients with MDR TB strains were female (median age 28 years), and 139 (76%) were male (median age 39 years). HIV testing was performed for 142 (80%) of 177 patients with MDR TB and 4 (57%) of 7 patients with XDR TB. Seven patients with MDR TB (4.9%) and no patient with XDR TB tested positive for HIV-1. Notably, 148 (80.4%) of 184 patients with MDR TB were immigrants from the FSU (online Appendix Figure, available from www.cdc.gov/EID/content/14/11/1700-appG.htm).

Ninety-four (53%) patients with MDR TB and 6 (86%) patients with XDR TB had previously received anti-TB treatment for >1 month ($p = 0.08$). Of the 100 previous-

RESEARCH

Table 1. Demographic and clinical characteristics of 184 patients with MDR TB and XDR TB, Germany*

Variables	MDR TB, n = 177	XDR TB, n = 7	p value	95% CI
Male gender, no. (%)	133 (75.1)	6 (85.7)	0.54	-0.37 to 0.17
Age, y, mean \pm SD	37.7 \pm 15.4	42.4 \pm 11.9	0.42	-16.33 to 6.93
Country of birth, no. (%)				
Former Soviet Union	142 (80.2)	6 (85.7)	0.74	-0.32 to 0.22
Germany	11 (6.2)	-	-	-
Others	24 (13.6)	1 (14.3)	0.93	-0.27 to 0.25
HIV positive, no. (%)	7/142 (4.9)	0	0.54	0.01 to 0.08
Kind of TB, no. (%)				
Pulmonary TB	162 (91.5)	6 (85.7)	0.59	-0.2 to 0.32
Extrapulmonary TB	5 (2.9)	-	-	-
Pulmonary and extrapulmonary TB	10 (5.6)	1 (14.3)	0.29	-0.34 to 0.16
Days in hospital, mean \pm SD	123.3 \pm 81	202 \pm 130	0.015†	-141.8 to -15.53
Previous TB treatment, no. (%)	94 (53)	6 (86)	0.08	-0.59 to 0.06
Resistance to all first-line drugs, no. (%)	64 (36)	6 (85.7)	0.008	-0.76 to -0.21
Resistance to fluoroquinolones, no. (%)	13/162 (8)	7 (100)	<0.001†	-0.96 to -0.87
Resistance to injectable second-line drugs, no. (%)	21/164 (12.8)	7 (100)	<0.001†	-0.92 to -0.83
Linezolid treatment, no. (%)	69 (39)	5 (71.4)	0.09	-0.66 to 0.02
Treatment outcome, no. (%)				
Cured	79 (44.6)	3 (42.8)	0.91	-0.35 to 0.39
Completed	26 (14.7)	1 (14.3)	1	-0.26 to 0.26
Successful treatment (cured + completed)	105 (59.3)	4 (57.1)	0.91	-0.35 to 0.39
Died	14 (7.9)	1 (14.3)	0.4	-0.32 to 0.18
Failure	1 (0.6)	-	-	-
Treatment failure (death or failure)	15 (8.4)	1 (14.3)	0.57	-0.32 to 0.2
Default	1 (0.6)	-	-	-
Transferred out	25 (14.1)	-	-	-
Uncertain outcome (default + transferred out)	26 (14.7)	-	-	-
Still on treatment	31 (17.5)	2 (28.6)	0.45	-0.44 to 0.22
Duration of therapy from beginning MDR treatment, mo, mean \pm SD	18 \pm 9	20 \pm 5	0.56	-8.78 to 4.78
Sputum smear conversion, no. (%)	98 (55.4)	5 (71.4)	0.4	-0.5 to 0.18
Culture conversion, no. (%)	132 (74.6)	5 (71.4)	0.85	-0.31 to 0.37
Sputum smear conversion, d, mean \pm SD	69.4 \pm 76	129.8 \pm 129.2	0.09	-132 to 11.2
Culture conversion, d, mean \pm SD	81.3 \pm 74.6	141 \pm 99.7	0.08	-127.6 to 8.2

*MDR, multidrug-resistant; TB, tuberculosis; XDR, extensively drug-resistant; CI, confidence interval.

†Significant result ($p < 0.05$).

ly treated patients, 89% were immigrants from the FSU, 6% from other countries, and 5% were born in Germany. Only 1 of the 7 patients with XDR TB had previously received directly observed treatment. Strains from patients with XDR TB had a significantly higher probability to be resistant to all first-line drugs (isoniazid, rifampin, pyrazinamide, ethambutol) (6/7, 85.7% vs. 64/177, 36%; $p = 0.08$) than strains from other patients with MDR TB. The median time from the onset of treatment to conversion of smear microscopy and culture to negative results was 88 days (mean \pm SD 129.8 \pm 129.2 days) and 117 days (mean \pm SD 141 \pm 99.7 days), respectively, with XDR TB vs. 53.5 days (mean \pm SD 69.4 \pm 76.1 days) and 61.5 days (mean \pm SD 81.3 \pm 74.6 days), respectively, with MDR TB.

Of 177 patients with MDR TB, 14 (7.9%) died, one's treatment failed (0.6%), 105 (59.3%) were treated successfully (6/105 underwent surgery), 31 (17.5%) were still receiving treatment, and 26 (14.7%) were lost to follow-up. Of 7 patients with XDR TB, 4 (57.1%) were treated

successfully (1/6 underwent surgery), 2 (28.6%) were still receiving treatment, and 1 (14.3%) died.

The overall treatment success including all patients was 59.2% (59.3% for patients with MDR TB and 57.1% for patients with XDR TB). After the 26 patients lost to follow-up were removed from the analysis, the treatment success rate increased to 69% (69.5% for patients with MDR TB and 57.1% for patients with XDR TB). When we also removed the 33 patients still receiving treatment, the treatment success rate increased to 87.2% (87.5% for patients with MDR TB and 80% for patients with XDR TB). Patients with XDR TB were less likely to achieve sputum-smear and culture conversion (5/7, 71.4% vs. 142/177, 80.2%; $p = 0.63$) and required a longer duration of hospitalization (mean \pm SD 202 \pm 130 vs. 123.3 \pm 81.0 days, $p = 0.015$) than patients with MDR TB. Logistic regression analysis of the association of treatment failure (death or failure) with potential covariates was performed; no statistical significant odds ratio was obtained on either

the univariate or multivariate analysis; a negative prognosis related to several variables could be seen, but sample size might have influenced the statistical results (Table 2). Treatment outcomes were compared between patients who were never treated and those who were previously treated with anti-TB drugs; no statistically significant difference was evident between the 2 groups (Table 3).

Seventy-four (40.2%) of the 184 study patients were treated with linezolid. Fifty-eight (78.4%) of them were born in the FSU, and 44 (59.5%) had received previous treatment. Two (2.7%) were HIV seropositive. *M. tuberculosis* isolates of patients receiving linezolid treatment were more frequently resistant to pyrazinamide (49/74, 66.2% vs. 30/110, 27.3%; $p < 0.001$), capreomycin (16/74, 21.6% vs. 3/110, 2.7%; $p < 0.001$), amikacin (15/74, 20.8% vs. 8/110, 7.3%; $p = 0.009$), fluoroquinolones (14/74, 18.9% vs. 6/110, 5.5%; $p = 0.004$) and cycloserine (6/74, 8.1% vs. 3/110, 2.7%; $p = 0.16$). Patients with XDR TB were more frequently treated with linezolid (5/7, 71.4% vs. 69/177, 38.9%; $p = 0.12$) than other patients with MDR TB. In the group of patients with linezolid treatment, the median time to sputum-smear conversion (XDR TB: 134 days vs. 44 days; MDR TB: 57 days vs. 36.5 days; log rank $p = 0.0213$) and to culture conversion (XDR TB: 160 days vs. 105 days; MDR TB: 68 days vs. 59 days; log rank $p = 0.0023$) was longer than in the group of patients not receiving linezolid (Figure). However, the duration of hospitalization was comparable in both groups (mean \pm SD 135.4 \pm 84.1 days with linezolid vs. 120.5 \pm 84.2 days without linezolid; $p = 0.241$) as was the case-fatality rate ($p = 0.28$). Different outcomes (e.g., successful treatment) were identified between those treated with linezolid versus those without linezolid (Table 4). Adverse effects ascribed to linezolid were observed in 25 (33.8%) of 74 cases (35% in cases with MDR and 20% in cases with XDR TB). Linezolid was interrupted in 19 (76%) of 25 cases and not reintroduced in 11 (58%) of 19 cases. Severe anemia appeared in 14 (56%) of 25 cases.

Sixty-four (36.2%) of 177 MDR TB patients showed resistance to pyrazinamide, ethambutol, or both. These patients were less likely to achieve sputum-smear and culture

conversion (49 [77%] of 64 vs. 93 [82%] of 113; $p = 0.36$) and were more frequently treated with linezolid (38 [60%] of 64 vs. 31 [27%] of 113; $p = 0.00003$). Thirty (47%) of them were successfully treated, 19 (30%) were still receiving treatment, one's treatment failed (2%), 10 (16%) were lost to follow-up, and 4 died (6%). Of 7 patients with XDR TB, 6 (86%) harbored strains that were resistant to pyrazinamide and ethambutol. Three (50%) of them achieved successful treatment outcome, 2 (33%) were still receiving treatment, and 1 (16.7%) died. These patients with XDR TB required longer hospitalization than those with MDR TB with resistance to pyrazinamide and ethambutol (mean \pm SD 210.7 \pm 140.1 vs. 132.5 \pm 92.8 days; $p = 0.063$).

Discussion

We present the results of our national survey on clinical parameters associated with MDR and XDR TB in a Western European country. Of the patients hospitalized with MDR or XDR TB in Germany who were included in this survey, 53% were treated previously against TB, and nearly 90% of them had immigrated from FSU countries. Relatively high treatment success rates were achieved with conventional medical treatment, intensified medical care, including long-term inpatient treatment, directly observed therapy, and use of third-line anti-TB drugs. Less than 6% of patients with MDR TB required a surgical intervention.

In the German observational cohort, the proportion of MDR TB among all TB cases was 4%. Strains of *M. tuberculosis* in 7 (3.8%) of 184 patients with MDR TB met the case definition for XDR TB, an infection now recognized as a global problem (10). Alarming reports on the spread of XDR TB among HIV-seropositive persons have been published recently for Kwa Zulu Natal, South Africa (12). While HIV coinfection was not a risk factor for XDR TB in our cohort, XDR TB was related to previous treatment mismanagement including the lack of directly observed therapy in FSU countries.

Patients with XDR TB have a higher risk for death and treatment failure than those with MDR TB (21,22). In infections with MDR TB, drug resistance to additional first-line

Table 2. Logistic regression analysis of the association of treatment failure (death and failure) with potential explanatory factors*

Variables	Crude OR (95% CI)	Adjusted OR (95% CI)
Male gender	4.46 (0.56–35.5)	5.8 (0.61–56.6)
Age, y	1.05 (1.01–1.09)	1.06 (1.01–1.1)
Immigrant status	1.18 (0.13–10.2)	0.7 (0.07–6.6)
HIV seropositivity	5 (0.76–32.6)	2.5 (0.28–22.1)
Previous anti-TB treatment >30 d	0.7 (0.26–2.2)	0.4 (0.11–1.3)
Streptomycin resistance	1.35 (0.15–11.4)	1.18 (0.13–10.69)
Ethambutol resistance	1.74 (0.52–5.7)	0.99 (0.29–3.3)
Pyrazinamide resistance	1.65 (0.57–4.7)	1.08 (0.35–3.3)
Fluoroquinolone resistance	1.67 (0.32–8.6)	0.86 (0.09–7.7)
Resistance to injectable second-line drugs	1.16 (0.3–4.5)	1.28 (0.31–5.2)
Resistance to all second-line drugs	1.18 (0.34–3.9)	1.35 (0.37–4.8)

*OR, odds ratio; CI, confidence interval; TB, tuberculosis.

Table 3. TB treatment outcomes in study patients not previously treated for TB compared with those treated previously for TB*

Treatment outcomes	No. (%) patients not treated previously, n = 84	No. (%) patients treated previously, n = 100	p value	95% CI
Cured	40 (47.6)	42 (42)	0.49	-0.09 to 0.19
Completed	8 (9.5)	19 (19)	0.05	-0.19 to -0.001
Successful treatment (cured + completed)	48 (57)	61 (61)	0.58	-0.18 to 0.1
Died	7 (8.3)	8 (8)	1	-0.07 to 0.07
Failure	1 (1.19)	-	-	-
Treatment failure (death or failure)	8 (9)	8 (8)	0.8	-0.07 to 0.09
Default	-	1 (1)	-	-
Transferred out	13 (15.5)	12 (12)	0.55	-0.06 to 0.12
Uncertain outcome (default + transferred out)	13 (15.5)	13 (13)	0.69	-0.08 to 0.12
Still receiving treatment	15 (17.9)	18 (18)	0.85	-0.12 to 0.1

*TB, tuberculosis; CI, confidence interval.

drugs other than isoniazid and rifampin has recently been shown to be a predictor of negative treatment outcomes (13). Resistance to fluoroquinolones and injectable second-line drugs (capreomycin in particular) also contributes to increased risk for treatment failure and death in these cases (23,24). XDR TB—defining drugs are those considered essential to achieve successful outcomes in MDR TB cases (9,17,24,25). While rapid direct sensitivity testing of *M. tuberculosis* for all cases with a suspicion of multidrug resistance is highly important, this technology is currently not available in many geographic areas with a high incidence of MDR TB.

Our findings support the observation that treatment success in cases with MDR TB is dependent on the number of drugs the strain is resistant to and the previous treatment history. The probability to observe any TB drug resistance or MDR TB has been shown to be 4-fold and 10-fold higher when patients have received TB treatment in the past (8,26,27).

As expected, patients infected with strains of XDR TB and MDR TB resistant to all first-line drugs were more likely to have a poor treatment outcome than patients infected with

other strains of multidrug-resistant *M. tuberculosis*. Patients with XDR TB required longer hospitalization and were less likely to achieve sputum-smear and culture conversion, although the latter result was not statistically significant.

More than 40% of patients in this cohort received off-label treatment against MDR or XDR TB with the oxazolidinone linezolid (28). In vitro and pharmacogenetic data suggest that oxazolidinones could be useful in management of mycobacterial infection, including MDR TB (29–32). However, clinical experience with the use of linezolid in the management of mycobacterial infections has been mainly restricted to case reports in nontuberculous mycobacterial diseases (33–35) and to a few case reports on patients with MDR TB (28,36,37). Cases of 24 patients with mycobacterial infections who were treated with linezolid were recently reviewed (38). Sterilization of mycobacterial cultures or resolution of symptoms was achieved in 15 (62.5%) of the 24 cases, although serious adverse events were observed in up to 75% of patients.

In this study, the description of 74 patients who were treated with linezolid against MDR or XDR TB in routine clinical practice substantially adds to the knowledge of the efficacy and tolerability of this drug. Drug toxicity from linezolid occurred in more than one third of patients and led to treatment discontinuation in 76% of them. Patients who were treated with linezolid had a much higher level of drug resistance than those who were not treated with this drug, and they had a longer time to sputum-smear and culture conversion. Nevertheless, patients who were treated with a linezolid-containing regimen experienced a sustained culture conversion rate of almost 80%. Despite the fact that patients who were treated with linezolid had a much higher level of drug resistance, the mortality rate was comparable to that of patients with fewer drug resistances who were not treated with linezolid. Drug resistance to linezolid in cases never treated previously (occasionally reported) (39) was extremely low in this cohort (1/184 patients with MDR TB). These data suggest that a linezolid-containing combination treatment might be an effective option against MDR or XDR TB. However, the high frequency of adverse




Figure. Kaplan-Meier plot showing the time to sputum smear conversion according to treatment received (linezolid-containing regimen, n = 74, vs. linezolid-sparing regimen, n = 110) in Germany (log-rank test 0.0924). The proportion of case-patients reaching conversion is shown along the vertical axis.

Table 4. TB treatment outcomes in study patients treated with linezolid compared with those not treated with linezolid*

Treatment outcomes	No. (%) patients treated with linezolid, n = 74	No. (%) patients not treated with linezolid, n = 110	p value	95% CI
Cured	21 (28.4)	61 (55.5)	0.0003†	-0.41 to -0.13
Completed	12 (16.2)	15 (13.6)	0.56	-0.07 to 0.13
Successful treatment (cured + completed)	33 (44.6)	76 (69.1)	0.0007†	-0.39 to -0.1
Died	8 (10.8)	7 (6.4)	0.31	-0.04 to 0.12
Failure	1 (1.4)	—	—	—
Treatment failure (death or failure)	9 (12.2)	7 (6.4)	0.15	-0.02 to 0.14
Default	—	1 (0.9)	—	—
Transferred out	10 (13.5)	15 (13.6)	0.98	-0.1 to 0.09
Uncertain outcome (default + transferred out)	10 (13.5)	16 (14.5)	0.84	-0.11 to 0.09
Still on treatment	22 (29.7)	11 (10)	0.0009†	0.07 to 0.3

*TB, tuberculosis; CI, confidence interval.

†Significant result ($p < 0.05$).

effects to linezolid warrants extreme caution when this drug is used for a prolonged period. Further investigations are needed to determine the best duration and dosage of linezolid treatment if the drug is to be routinely used as a life-saving therapy in cases of MDR or XDR TB.

In this cohort, most patients with MDR TB for whom complete treatment data were available were treated for a 24-month period with a combination treatment of 4 or 5 effective drugs. Long-term inpatient care (mean \pm SD 202 \pm 130 days for XDR TB and 123.3 \pm 81.0 days for MDR TB) and availability of all third-line drugs was necessary to achieve an overall treatment success rate of 59% (overall sample) to 87% (excluding patients still receiving treatment and lost to follow-up) in the German TBNET hospitals. The results are consistent with those of previous studies showing overall treatment success rates in MDR TB of 54% (13) and 62% (40).

The study has several limitations. Fourteen percent of patients were lost to follow-up by their hospital physicians. Their clinical outcome is uncertain. Complete data on previous treatment regimens were not available for most patients with recurrent TB who immigrated from FSU countries. Additional factors, including variability of provider treatment practices in the patients' native countries and existence of additional co-existing conditions, may have confounded the results of our analysis. The proportion of patients with strains of *M. tuberculosis* with more advanced drug resistance was higher among the 27 participating hospitals of the German TBNET than other hospitals in Germany, which are not specialized in TB treatment. Data for 35% of patients with MDR TB who were identified in Germany during the time of the survey were not available for this study as their cases were not diagnosed and treated in a hospital participating in this survey, which could have resulted in a selection bias. Nevertheless, the large and representative sample size, the availability of treatment outcomes, and the quality of laboratory data (all XDR TB-defining drugs tested and drug susceptibility tests controlled for quality) strengthen the results of this study.

In conclusion, cases of MDR and XDR TB in Germany appear to be largely restricted to immigrants from FSU countries. Previous treatment mismanagement is the probable cause of *M. tuberculosis* drug-resistance selection in most of these patients. Off-label treatment with linezolid is frequently used to treat advanced cases of MDR and XDR TB in Germany, despite high rates of adverse effects and paucity of clinical evidence for safety, tolerability, and efficacy of this medication. Relatively high sustained culture conversion rates can still be achieved in advanced cases of MDR and XDR TB; this requires high level, labor-intensive, and costly case management, including quality-controlled drug-susceptibility testing for all second-line drugs, long-term inpatient care, directly observed therapy, and availability of all third-line drugs. However, these resources are currently not available for patients with MDR or XDR TB in many other places outside Western Europe.

Dr Eker, after an appointment at the State of Schleswig-Holstein (Germany) Central Institution for Asylum-seekers, began a residency in Internal Medicine/Pulmonary Medicine at the Medical Clinic of the Research Center Borstel in 2007, where she is affiliated with the Division of Clinical Infectious Diseases. She is a member of TBNET.

References

1. World Health Organization. WHO report 2007; global tuberculosis control, surveillance, planning, financing. Geneva: The Organization; 2007.
2. World Health Organization. WHO report 2008; global tuberculosis control, surveillance, planning, financing. Geneva: The Organization; 2008.
3. Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, et al. Global incidence of multidrug-resistant tuberculosis. *J Infect Dis.* 2006;194:479-85. DOI: 10.1086/505877
4. Aziz MA, Wright A, Laszlo A, De Muyck A, Portaels F, Van Deun A, et al. Epidemiology of antituberculosis drug resistance (the global project on anti-tuberculosis drug resistance surveillance): an updated analysis. *Lancet.* 2006;368:2142-54. DOI: 10.1016/S0140-6736(06)69863-2

5. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, et al. Global trends in resistance to antituberculosis drugs. World Health Organization–International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. *N Engl J Med*. 2001;344:1294–303. DOI: 10.1056/NEJM200104263441706
6. WHO launches new Stop TB strategy to fight the global tuberculosis epidemic. *Indian J Med Sci*. 2006;60:125–6.
7. World Health Organization. Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: The Organization; 2008.
8. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva: The Organization; 2006.
9. Centers for Disease Control and Prevention. Emergence of *Mycobacterium tuberculosis* with extensive resistance to second-line drugs—worldwide, 2000–2004. *MMWR Morb Mortal Wkly Rep*. 2006;55:301–5.
10. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martin-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis. *Emerg Infect Dis*. 2007;13:380–7.
11. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. *Lancet*. 2005;365:318–26.
12. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. *Lancet*. 2006;368:1575–80. DOI: 10.1016/S0140-6736(06)69573-1
13. Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toun-goussova OS, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. *Eur Respir J*. 2007;30:623–6. DOI: 10.1183/09031936.00077307
14. Robert-Koch-Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2006. Berlin: The Institute; 2008.
15. Rieder HL, Zellweger JP, Raviglione MC, Keizer ST, Migliori GB. Tuberculosis control in Europe and international migration. *Eur Respir J*. 1994;7:1545–53. DOI: 10.1183/09031936.94.07081545
16. Laszlo A, Rahman M, Espinal M, Raviglione M. Quality assurance programme for drug susceptibility testing of *Mycobacterium tuberculosis* in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994–1998. *Int J Tuberc Lung Dis*. 2002;6:748–56.
17. Extensively drug-resistant tuberculosis (XDR TB): recommendations for prevention and control. *Wkly Epidemiol Rec*. 2006;81:430–2.
18. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis*. 2005;9:640–5.
19. Robert-Koch-Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2004. Berlin: The Institute; 2006.
20. Robert-Koch-Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2005. Berlin: The Institute; 2007.
21. Migliori GB, Lange C, Girardi E, Centis R, Besozzi G, Kliiman K, et al. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results. *Clin Infect Dis*. 2008;46:958–9. DOI: 10.1086/528875
22. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. *Clin Infect Dis*. 2007;45:1290–5. DOI: 10.1086/522537
23. Migliori GB, Lange C, Girard E, Centis R, Besozzi G, Kliiman K, et al. Fluoroquinolones: Are they essential to treat multidrug-resistant tuberculosis? *Eur Respir J*. 2008;31:904–5. DOI: 10.1183/09031936.00159807
24. Migliori GB, Lange C, Centis R, Sotgiu G, Muetterlein R, Hoffmann H, et al. Does resistance to second-line injectables lead to worse treatment outcomes in MDR and XDR TB? *Eur Respir J*. 2008;31:9904–10.
25. Migliori GB, Ortmann J, Girardi E, Besozzi G, Lange C, Cirillo DM, et al. Extensively drug-resistant tuberculosis, Italy and Germany. *Emerg Infect Dis*. 2007;13:780–2.
26. Zignol M, Wright A, Jaramillo E, Nunn P, Raviglione MC. Patients with previously treated tuberculosis no longer neglected. *Clin Infect Dis*. 2007;44:61–4. DOI: 10.1086/509328
27. Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali RE, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. *Int J Tuberc Lung Dis*. 2001;5:887–93.
28. Fortun J, Martin-Davila P, Navas E, Perez-Elias MJ, Cobo J, Tato M, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. *J Antimicrob Chemother*. 2005;56:180–5. DOI: 10.1093/jac/dki148
29. Alcalá L, Ruiz-Serrano MJ, Pérez-Fernández Turegano C, Garcia De Viedma D, Diaz-Infantes M, Marin-Arriaza M, et al. In vitro activities of linezolid against clinical isolates of *Mycobacterium tuberculosis* that are susceptible or resistant to first-line antituberculous drugs. *Antimicrob Agents Chemother*. 2003;47:416–7. DOI: 10.1128/AAC.47.1.416-417.2003
30. Diekema DJ, Jones RN. Oxazolidinone antibiotics. *Lancet*. 2001;358:1975–82. DOI: 10.1016/S0140-6736(01)06964-1
31. Molicotti P, Ortu S, Bua A, Cannas S, Sechi LA, Zanetti S. In vitro efficacy of linezolid on clinical strains of *Mycobacterium tuberculosis* and other mycobacteria. *New Microbiol*. 2006;29:275–80.
32. Tato M, de la Pedrosa EG, Canton R, Gomez-Garcia I, Fortun J, Martin-Davila P, et al. In vitro activity of linezolid against *Mycobacterium tuberculosis* complex, including multidrug-resistant *Mycobacterium bovis* isolates. *Int J Antimicrob Agents*. 2006;28:75–8. DOI: 10.1016/j.ijantimicag.2006.02.011
33. Brown-Elliott BA, Wallace RJ Jr, Blinkhorn R, Crist CJ, Mann LB. Successful treatment of disseminated *Mycobacterium chelonae* infection with linezolid. *Clin Infect Dis*. 2001;33:1433–4. DOI: 10.1086/322523
34. Kyle SD, Porter WM. *Mycobacterium chelonae* infection successfully treated with oral clarithromycin and linezolid. *Br J Dermatol*. 2004;151:1101. DOI: 10.1111/j.1365-2133.2004.06230.x
35. Nannini EC, Keating M, Binstock P, Samonis G, Kontoyiannis DP. Successful treatment of refractory disseminated *Mycobacterium avium* complex infection with the addition of linezolid and mefloquine. *J Infect*. 2002;44:201–3. DOI: 10.1053/jinf.2002.0970
36. Yew WW, Chau CH, Wen KH. Linezolid in the treatment of “difficult” multidrug-resistant tuberculosis. *Int J Tuberc Lung Dis*. 2008;12:345–6.
37. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR TB)—a report of ten cases. *J Infect*. 2006;52:92–6. DOI: 10.1016/j.jinf.2005.04.007
38. Ntziora F, Falagas ME. Linezolid for the treatment of patients with atypical mycobacterial infections: a systematic review. *Int J Tuberc Lung Dis*. 2007;11:606–11.
39. Richter E, Rusch-Gerdes S, Hillemann D. First linezolid-resistant clinical isolates of *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*. 2007;51:1534–6. DOI: 10.1128/AAC.01113-06
40. Cox HS, Kalon S, Allamuratova S, Sizaire V, Tigay ZN, Rusch-Gerdes S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR TB among treatment failures. *PLoS One*. 2007;2:e1126. DOI: 10.1371/journal.pone.0001126

Address for correspondence: Christoph Lange, Division of Clinical Infectious Diseases, Research Center Borstel, Parkallee 35, 23845 Borstel, Germany; email: clange@fz-borstel.de

Appendix Table. Clinical characteristics among patients with XDR TB, Germany

Country of birth	Age, y	Gender	Radiology at XDR diagnosis	Previous treatment, >30 d	Drugs received during previous treatment†	Drug-resistance at XDR diagnosis†	Drugs used in current treatment†	Hospital stay, d	Smear conversion, d	Culture conversion, d	Outcome	TX duration, mo
Azerbaijan	52	M	Monolateral cavity	Y	Unknown	Am, Cm, Cs, E, FQ, H, PAS, R, Rb, S, Z	Eto, Lzd + surgery	224	7	35	Died	24
China	33	F	Generalized lymphadenopathy	N	NA	Am, Cm, E, FQ, H, R, S, Z	Cs, Eto, Rb,	59	44	93	TX completed	26
Uzbekistan	33	M	Monolateral cavity	Y	E, H, R, S,Z	Am, Cm, E, Eto, FQ, H, R, Rb, S, Z	Cm, Cs, Lzd,	120	Not achieved	Not achieved	Chronic in treatment	17
Uzbekistan	29	M	Bilateral cavities	Y	E, H, R, Rb S, Z	Am, Cm, E, FQ, H, R, Rb, S, Z	Cs, Eto, Lzd, Rb	240	180	160	TX completed	12
Russian Federation	60	M	Monolateral cavity	Y	E, H, R,Z,	Am, E, FQ, H, R, Rb, S	Cm, Eto , FQ, PAS, Z	150	Unknown	117	TX completed	24
Ukraine	50	M	Bilateral cavities	Y	Unknown	Cm, E, Eto, FQ, H, R, Rb S, Z	Am, Cs, Lzd, PAS	159	88	Not achieved	Chronic in treatment	15
Ukraine	42	M	Bilateral cavities	Y	Unknown	Am, Cm, E, Eto, FQ, H, R, Rb, Z	Cs, Lzd, PAS, S	462	330	300	TX completed	15

*XDR TB, extensively-drug resistant tuberculosis; TX, treatment; Y, yes; N, no; NA, not applicable.

†First-line drugs: H, isoniazid; E, ethambutol; R, rifampin; S, streptomycin; Z, pyrazinamide. Second- and third-line drugs: Am, amikacin; Cm, capreomycin; Cs, cycloserine; Eto, ethionamide; FQ, fluoroquinolone; Lzd, linezolid; PAS, para-aminosalicylic acid; Rb, rifabutin.